Carbiotix, an award-winning spin-off company from the department of biotechnology at Lund University, Sweden focused on optimizing gut health via personalized prebiotics, today announced that it will start investigating if its technology platform can be used to diagnose, prevent and even treat many leading chronic diseases such as type 2 diabetes, cardiovascular disease, arthritis, some forms of cancer, and even Alzheimer’s and dementia.
“We have always had the ambition of leveraging our technology platform to develop, test, and increase the effectiveness of gut microbiome therapeutics. This new investigation into diagnosing, preventing and potentially even treating chronic conditions is a natural extension of this ambition and is based on very promising customer data we have generated after the recent launch of our personalized prebiotic fiber,” says Carbiotix CEO, Kristofer Cook.
“Early detection is by far the most important factor when treating any chronic disease, and we have seen indications that an optimized and stable gut flora is highly sensitive to inflammation, one response the body has in the early stages of chronic disease development. This information could be used to alarm someone, like an early warning system, that they should visit a medical professional if the inflammation is sudden, sustained and unexplained. Alternatively, it may also be possible to link the activity of specific gut bacteria to the onset of a chronic condition, thus we could potentially be able to diagnose a chronic disease in real-time, as our customers already have the routine of sending us monthly gut microbiome samples,” says Carbiotix CTO, Peter Falck.
“We also think that an optimized and stable gut flora will generally result in less inflammation in the body (a suspected and potential trigger to the development of many chronic conditions), and an improved resistance against bacterial infections, potentially even rebounding to an optimal state much quicker after the use of antibiotics. Of course, all of these observations and theories will need to be validated through clinical studies and approved by the respective regulatory authorities before we can communicate that we can diagnose, prevent or treat a specific chronic condition. However, informing customers of potentially unexplained inflammation in the body is something we can do today and will further improve over time as more people join our platform and send us monthly samples. The key to this approach is to first optimize and stabilize a persons’ gut health through personalized soluble fiber consumption and monthly gut microbiome testing. At the end of the day, you can’t manage what you don’t measure,” says Falck.
Carbiotix approach focuses primarily on addressing the potential causes of chronic disease development (ie. prevention) rather than treating symptoms, leveraging host probiotic bacteria and “food as medicine” to restore and optimize the gut microbiome. All activities at Carbiotix are steered by three facts related to the microbiome:
“Although we launched our technology platform less than 6 months ago, the results we are seeing in this time-frame are astonishing. Nearly all of our customers, including people with stated gastrointestinal problems, experience gut health improvements after 2-4 months, with some even reaching an optimized and stable gut flora in this time-frame. Since the rate of chronic disease development continues to grow around the world, it is now more important than ever to explore new and unconventional approaches, especially those that leverage the body’s own natural ability to repair itself. What is being done now is obviously not enough to reverse this trend. Moreover, if there is any truth to Hippocrates statement that “all disease begins in the gut”, we could potentially hold an important key in the fight against many chronic diseases, something that could positively impact the lives of millions of people around the world,” says Cook.